$MBRX
Moleculin Biotech, Inc.

2017 Q3 Form 10-Q Financial Statement

#000114420417042482 Filed on August 11, 2017

View on sec.gov

Income Statement

Concept 2017 Q3 2017 Q2 2016 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.340M $800.0K $620.0K
YoY Change 45.65% 29.03%
% of Gross Profit
Research & Development $1.061M $515.0K $105.0K
YoY Change 113.48% 390.48%
% of Gross Profit
Depreciation & Amortization $5.000K $5.000K $1.000K
YoY Change 400.0% 400.0%
% of Gross Profit
Operating Expenses $2.404M $1.320M $724.0K
YoY Change 69.06% 82.32%
Operating Profit -$2.404M -$1.320M -$724.0K
YoY Change 69.06% 82.32%
Interest Expense $1.000K $0.00 $15.00K
YoY Change -90.0% -100.0%
% of Operating Profit
Other Income/Expense, Net $9.000K $0.00
YoY Change
Pretax Income -$2.870M -$3.420M -$740.0K
YoY Change 100.7% 362.16%
Income Tax
% Of Pretax Income
Net Earnings -$2.866M -$3.424M -$739.0K
YoY Change 100.14% 363.33%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$839.2K -$1.148M -$493.3K
COMMON SHARES
Basic Shares Outstanding 20.26M shares 17.76M shares 11.23M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q3 2017 Q2 2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.740M $9.270M $7.240M
YoY Change 41.42% 28.04%
Cash & Equivalents $8.736M $9.272M $7.245M
Short-Term Investments
Other Short-Term Assets $730.0K $810.0K $320.0K
YoY Change 204.17% 153.13%
Inventory
Prepaid Expenses $809.0K $315.1K
Receivables
Other Receivables
Total Short-Term Assets $9.463M $10.08M $7.560M
YoY Change 47.2% 33.35%
LONG-TERM ASSETS
Property, Plant & Equipment $22.00K $20.00K $7.168K
YoY Change 34.59% 179.02%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $11.17M $11.17M $11.67M
YoY Change 0.22% -4.33%
TOTAL ASSETS
Total Short-Term Assets $9.463M $10.08M $7.560M
Total Long-Term Assets $11.17M $11.17M $11.67M
Total Assets $20.63M $21.25M $19.23M
YoY Change 17.41% 10.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.090M $650.0K $970.0K
YoY Change 11.22% -32.99%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $430.0K
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $1.832M $1.830M $1.403M
YoY Change 43.11% 30.46%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $600.0K
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $150.0K $150.0K $600.0K
YoY Change 200.0% -75.0%
Total Long-Term Liabilities $150.0K $150.0K $600.0K
YoY Change 200.0% -75.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.832M $1.830M $1.403M
Total Long-Term Liabilities $150.0K $150.0K $600.0K
Total Liabilities $1.982M $1.980M $2.003M
YoY Change 49.01% -1.14%
SHAREHOLDERS EQUITY
Retained Earnings -$11.30M -$8.429M -$2.076M
YoY Change 247.39% 305.98%
Common Stock $29.95M $27.71M $19.31M
YoY Change 53.58% 43.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $18.65M $19.27M $17.23M
YoY Change
Total Liabilities & Shareholders Equity $20.63M $21.25M $19.23M
YoY Change 17.41% 10.48%

Cashflow Statement

Concept 2017 Q3 2017 Q2 2016 Q2
OPERATING ACTIVITIES
Net Income -$2.866M -$3.424M -$739.0K
YoY Change 100.14% 363.33%
Depreciation, Depletion And Amortization $5.000K $5.000K $1.000K
YoY Change 400.0% 400.0%
Cash From Operating Activities -$1.610M -$1.930M -$1.360M
YoY Change 69.47% 41.91%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $0.00
YoY Change 0.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $30.00K
YoY Change -100.0%
Cash From Investing Activities -$10.00K $0.00 $30.00K
YoY Change -90.91% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $400.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.090M 2.320M 8.310M
YoY Change -72.08%
NET CHANGE
Cash From Operating Activities -1.610M -1.930M -1.360M
Cash From Investing Activities -10.00K 0.000 30.00K
Cash From Financing Activities 1.090M 2.320M 8.310M
Net Change In Cash -530.0K 390.0K 6.980M
YoY Change -50.0% -94.41%
FREE CASH FLOW
Cash From Operating Activities -$1.610M -$1.930M -$1.360M
Capital Expenditures -$10.00K $0.00
Free Cash Flow -$1.600M -$1.930M
YoY Change 70.21%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q2 us-gaap Assets Current
AssetsCurrent
10081000 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23000 USD
CY2017Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-8429000 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4675000 USD
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
19623000 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
5222000 USD
CY2017Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
27711000 USD
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
19269000 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
14960000 USD
CY2017Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21249000 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16393000 USD
CY2017Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
809000 USD
CY2016Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
215000 USD
CY2017Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20000 USD
CY2016Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
0 USD
CY2017Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
0 USD
CY2017Q2 us-gaap Assets
Assets
21249000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5007000 USD
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9272000 USD
CY2017Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
1185000 USD
CY2016Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
0 USD
us-gaap Net Income Loss
NetIncomeLoss
-3754000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
219000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-160000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3323000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-4000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
7592000 USD
CY2017Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1830000 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1345000 USD
CY2017Q2 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
150000 USD
CY2016Q4 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
88000 USD
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1069000 USD
CY2016Q4 us-gaap Assets
Assets
16393000 USD
CY2017Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0 USD
CY2016Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0 USD
CY2017Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5000 USD
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
515000 USD
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
800000 USD
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
1320000 USD
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1320000 USD
CY2017Q2 us-gaap Interest Expense
InterestExpense
0 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-3424000 USD
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17863707 shares
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
618000 USD
CY2016Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1000 USD
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
724000 USD
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-724000 USD
CY2016Q2 us-gaap Interest Expense
InterestExpense
15000 USD
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-739000 USD
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8875173 shares
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
105000 USD
CY2017Q2 mbrx Gain From Settlement Liability
GainFromSettlementLiability
0 USD
CY2016Q2 mbrx Gain From Settlement Liability
GainFromSettlementLiability
0 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4265000 USD
us-gaap Interest Paid
InterestPaid
0 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8000 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
595000 USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
4460000 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
302000 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
us-gaap Net Income Loss
NetIncomeLoss
-1071000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1000 USD
CY2016Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
180000 USD
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
us-gaap Share Based Compensation
ShareBasedCompensation
162000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-422000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1645000 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
201000 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
165000 USD
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7245000 USD
us-gaap Interest Paid
InterestPaid
48000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0 USD
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
89000 USD
us-gaap Deferred Compensation Arrangement With Individual Compensation Expense
DeferredCompensationArrangementWithIndividualCompensationExpense
63000 USD
us-gaap Deferred Compensation Arrangement With Individual Compensation Expense
DeferredCompensationArrangementWithIndividualCompensationExpense
0 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
315000 USD
mbrx Gain From Settlement Liability
GainFromSettlementLiability
149000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3132000 USD
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
0 USD
CY2016Q2 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
1166503 shares
us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
2920738 shares
CY2017Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2017Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20164854 shares
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20164854 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12164852 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12164852 shares
CY2017Q2 us-gaap Sales Revenue Net
SalesRevenueNet
0 USD
CY2016Q2 us-gaap Sales Revenue Net
SalesRevenueNet
0 USD
us-gaap Sales Revenue Net
SalesRevenueNet
0 USD
us-gaap Sales Revenue Net
SalesRevenueNet
0 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1199000 USD
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Registrant Name
EntityRegistrantName
Moleculin Biotech, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001659617
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Trading Symbol
TradingSymbol
MBRX
CY2017Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20261904 shares
CY2017Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
14000 USD
CY2017Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6000 USD
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
300000 USD
CY2017Q2 us-gaap Interest Payable Current
InterestPayableCurrent
30000 USD
CY2017Q1 mbrx Stock Issued During Period Shares For Cash Initial Public Offering Net Of Stock Issuance Costs
StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts
3710000 shares
CY2017Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1060000 USD
CY2017Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
1240000 USD
CY2016Q2 mbrx Shares Authorized
SharesAuthorized
80000000 shares
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2016Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q2 mbrx Estimated Forfeiture Rate Percentage
EstimatedForfeitureRatePercentage
0 pure
CY2017Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1300000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y14D
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0 pure
CY2016Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
1000000 USD
CY2016Q2 us-gaap Business Combination Consideration Transferred Equity Interests Issued And Issuable
BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
750000 USD
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2017-06-30
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
120000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1649000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
923000 USD
us-gaap Operating Expenses
OperatingExpenses
2856000 USD
us-gaap Operating Expenses
OperatingExpenses
1044000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-2856000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-1044000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2283000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
mbrx Gain From Settlement Liability
GainFromSettlementLiability
0 USD
CY2016Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2017Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3342000 USD
us-gaap Interest Expense
InterestExpense
1000 USD
us-gaap Interest Expense
InterestExpense
27000 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
1000 USD
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
0 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16137312 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7796782 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
mbrx Stock Issued During Period Value For Cash Initial Public Offering Net Of Stock Issuance Costs
StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts
317000 USD
mbrx Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
7135000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
220000 USD
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
302000 USD
CY2017Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.35
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
550000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Use of Estimates in Financial Statement Presentation -</font></strong> <font style="FONT-SIZE: 10pt">The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt"> Reclassifications &#150;</font></strong> <font style="FONT-SIZE: 10pt">A reclassification was made to the December 31, 2016 financial statements to conform to the 2017 presentation. Such reclassification did not affect net loss as previously reported. Historically, accrued interest associated with &#8220;convertible notes payable&#8217; was included in the line item &#8220;accounts payable and accrued expense&#8221;. Management believes that these costs are best shown included in the amounts shown for &#8220;convertible notes payable&#8221; and, as such, a reclassification was made to the balance sheet for the year ended December 31, 2016 by reducing &#8220;accounts payable and accrued expenses&#8221; and increasing &#8220;convertible notes payable&#8221; by $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.02</font> million.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016 us-gaap Increase Decrease In Notes Payable Current
IncreaseDecreaseInNotesPayableCurrent
20000 USD
CY2016 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0 pure
CY2016 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0 pure
CY2016 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P0Y
us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
CY2016 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
CY2015Q4 mbrx Milestone Payment Description
MilestonePaymentDescription
The amended milestone payments are as follows: (i) commencement of Phase III Study for first licensed drug/product within the United States, Europe, China or Japan - $150,000; (ii) submission of the first NDA within the United States - $500,000; and (iii) receipt of first marketing approval for sale of a license product in the United States- $600,000.
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
20000 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
530000 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
50000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.76
CY2017Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.33
mbrx Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue
0.14
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.31
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.17
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.20
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M14D
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
83500 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M25D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P2Y11M1D
CY2016Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
11148000 USD
CY2017Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q2 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
100000 USD
CY2017Q2 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
11148000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
83500 USD
CY2017Q2 mbrx Gain Loss From Expiration Of Warrants
GainLossFromExpirationOfWarrants
1238000 USD
CY2016Q2 mbrx Gain Loss From Expiration Of Warrants
GainLossFromExpirationOfWarrants
0 USD
mbrx Gain Loss From Expiration Of Warrants
GainLossFromExpirationOfWarrants
1238000 USD
mbrx Gain Loss From Expiration Of Warrants
GainLossFromExpirationOfWarrants
0 USD
us-gaap Noncash Or Part Noncash Acquisition Payables Assumed1
NoncashOrPartNoncashAcquisitionPayablesAssumed1
0 USD
us-gaap Noncash Or Part Noncash Acquisition Payables Assumed1
NoncashOrPartNoncashAcquisitionPayablesAssumed1
100000 USD
us-gaap Stock Issued1
StockIssued1
0 USD
us-gaap Stock Issued1
StockIssued1
9774000 USD
CY2017Q2 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
804098 shares
CY2017Q2 mbrx Class Of Warrant Or Right Outstanding Amount Receivable
ClassOfWarrantOrRightOutstandingAmountReceivable
34000 USD
CY2016Q4 mbrx Class Of Warrant Or Right Outstanding Amount Receivable
ClassOfWarrantOrRightOutstandingAmountReceivable
0 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
470000 USD
mbrx Warrants Excercised Not Yet Paid
WarrantsExcercisedNotYetPaid
34000 USD
mbrx Warrants Excercised Not Yet Paid
WarrantsExcercisedNotYetPaid
0 USD
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
510000 shares
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.40
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.28
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
48500 USD
CY2017Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1240000 USD

Files In Submission

Name View Source Status
0001144204-17-042482-index-headers.html Edgar Link pending
0001144204-17-042482-index.html Edgar Link pending
0001144204-17-042482.txt Edgar Link pending
0001144204-17-042482-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mbrx-20170630.xml Edgar Link completed
mbrx-20170630.xsd Edgar Link pending
mbrx-20170630_cal.xml Edgar Link unprocessable
mbrx-20170630_def.xml Edgar Link unprocessable
mbrx-20170630_lab.xml Edgar Link unprocessable
mbrx-20170630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v471975_10q.htm Edgar Link pending
v471975_ex31-1.htm Edgar Link pending
v471975_ex31-2.htm Edgar Link pending
v471975_ex32-1.htm Edgar Link pending
v471975_ex32-2.htm Edgar Link pending
v471975_img01.jpg Edgar Link pending